LGC releases clinical diagnostic kit for COVID-19 variant analysis

This solution is compatible with multiple applications, including performance confirmation for existing SARS-CoV-2 molecular assays as well as SARS-CoV-2 variant genotyping or NGS assays

LGC SeraCare has expanded its line of SARS-CoV-2 molecular quality solutions to include AccuPlex SARS-CoV-2 variant panel 1. The kit contains SARS-CoV-2 genomic RNA with a focus on S-gene mutations in three prominent variants of concern (UK variant B.1.1.7, South Africa variant B.1.351, and Brazil variant P.1) with vials for each variant as well as wild type control and human RNase P negative control vials.

This solution is compatible with multiple applications, including performance confirmation for existing SARS-CoV-2 molecular assays as well as SARS-CoV-2 variant genotyping or NGS assays.

LGC SeraCare’s AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient, the company says. These materials serve as quality control solutions to challenge the entire molecular test procedure, LGC suggests, making them the preferred alternative to infectious materials.

Bharathi Anekella, Executive VP and General Manager, LGC Clinical Diagnostics, said: “As vaccine deployment efforts are proving to be effective in slowing the spread of SARS-CoV-2, the diagnostic community focus has shifted towards monitoring and surveillance of emerging variants. AccuPlex recombinant material is an ideal tool to support IVD development and diagnostic quality control efforts and we are proud to use this technology to produce solutions for variant analysis to help us move beyond the COVID-19 pandemic.”

Companies